Reviva to Participate in the BIO International Convention
Reviva to Participate in the BIO International Convention
CUPERTINO, Calif., May 21, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the BIO International Convention, taking place June 3-6, 2024, in San Diego, CA.
加利福尼亞州庫比蒂諾，2024年5月21日——Reviva Pharmicals Holdings, Inc.（納斯達克股票代碼：RVPH）（“Reviva” 或 “公司”）是一家開發旨在解決中樞神經系統（CNS）、炎症和心臟代謝疾病領域未得到滿足的醫療需求的療法的後期製藥公司，今天宣佈，Laxminarayan Bhat博士，創始人、總裁兼首席執行官 Reviva將參加2024年6月3日至6日在加利福尼亞州聖地亞哥舉行的BIO國際大會的小組討論。
| BIO International Convention |
| Panel Title: Challenging Biotech's One-Track Mind When it Comes to Neuropsychiatric Drug Innovation Date: Tuesday, June 4, 2024 Time: 4:15 p.m PT Location: San Diego, CA |
| BIO 國際大會 |
| 小組標題： 在神經精神藥物創新方面，挑戰生物技術公司的單軌思維 日期：2024 年 6 月 4 日，星期二 時間：太平洋時間下午 4:15 地點：加利福尼亞州聖地亞哥 |
To register for the convention please use the link HERE.
要註冊參加大會，請使用鏈接 這裏。
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
關於 Reviva
Reviva是一家處於後期階段的生物製藥公司，致力於爲社會、患者及其家庭帶來未得到滿足的醫療需求和負擔的疾病發現、開發和尋求將下一代療法商業化。Reviva目前的產品線側重於中樞神經系統（CNS）、炎症和心臟代謝疾病。Reviva的產品線目前包括兩種候選藥物，即brilaroxazine（RP5063）和 RP1208。兩者都是內部發現的新化學實體。Reviva 已在美國、歐洲和其他幾個國家獲得了 brilaroxazine 和 RP1208 的物質組合專利。
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
公司聯繫人：
Reviva 製藥控股有限公司
Laxminarayan Bhat，博士
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
投資者關係聯繫人：
LifeSci 顧問有限公司
布魯斯·麥克爾
bmackle@lifesciadvisors.com
Media Contact:
Kristin Politi
kpoliti@lifescicomms.com
(646) 876-4783
媒體聯繫人：
克里斯汀·波利蒂
kpoliti@lifescicomms.com
(646) 876-4783
譯文內容由第三人軟體翻譯。